3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Tumor-Agnostic
1
Gynecologic
1
Genitourinary
1
Conditions
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
8
Sunitinib
7
enfortumab vedotin
6
Abiraterone Acetate
6
enzalutamide
5
Nivolumab
5
Gemcitabine
5
Cisplatin
5
Carboplatin
4
avelumab
3
Prednisone
3
Ipilimumab
3
Docetaxel
3
Androgen Antagonists
3
sacituzumab govitecan
2
olaparib
2
niraparib
2
erdafitinib
2
entrectinib
2
durvalumab
2
darolutamide
2
cabozantinib
2
belzutifan
2
apalutamide
2
Pluvicto
2
Mitomycin
2
Leuprolide
2
Everolimus
2
Axitinib
2
zimberelimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
lenvatinib
×
Genitourinary
×
Clear all
NCT02811861
2026-02-23
CLEAR
Eisai Inc.
Phase 3
Active not recruiting
1,069 enrolled
12 charts
1 FDA